![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
24/1/2012 16:11 | Something fishy going on - we get a couple of small sized purchases and now there is NO stock available to buy online without a negotiated trade - not a single share. Maybe the source of sub-placing price stock has dried up. Could see a spike soon. EDIT: obviously MMs needed a breather as normal service is resumed (16:18) although there are only 15K available online at the full offer. | ![]() longshanks | |
23/1/2012 11:22 | Yes. I thought the sell off of ODX was overdone even if growth in sales of IDS-iSYS was slowing. It's doubly overdone IMO on today's positive news about IDS-iSYS. | ![]() somerset lad | |
23/1/2012 10:00 | somerset lad - thanks very much a very interesting post. So reading between the lines it's fairly good news for us at ODX then? | ![]() monis | |
23/1/2012 09:30 | MONIS, the link between ODX and IDH is that ODX's growth strategy involves (in part) developing product for IDH's IDS-iSYS platform; and the more successful IDH is in selling its IDS-iSYS systems, the larger the addressable market for ODX if its product development succeeds. ODX holders therefore do not care about: (a) the prospects for IDH's vitamin D tests (which account for around half of IDH's revenues); or (b) IDH's margins in selling IDS-iSYS systems; although both of these points are very important for IDH holders. (ODX holders are interested indirectly in IDH investing to increase the range of tests available on IDS-iSYS systems and in IDH investing in sales and marketing for the IDS-iSYS system, since both of these ought to drive sales of the IDS-iSYS system. In turn, therefore, it helps ODX if IDH is successful generally and generates enough cash to fund product development and marketing.) Today's IDH statement is bearish on vitamin D testing (but we don't care), bullish on IDS-iSYS (as Stegrego notes above; very good news), and also makes encouraging noises on new product development, marketing investment and cash generation. This message (vitamin D bad; IDS-iSYS good) contrasts with IDH's warning on 28.11.11 which could be read as bearish on both of these components of the IDH business and led (IMO) to the sustained fall in the ODX share price | ![]() somerset lad | |
23/1/2012 08:37 | Is it possible that we at ODX could be taking business away from them? Or are we not linked like that? | ![]() monis | |
23/1/2012 08:28 | IDH are positive on IDS -iSYS. Investment in new product development will increase in the new financial year. The Company believes that the IDS-iSYS proposition remains strong and fulfils a significant unmet market need particularly for the small and medium sized laboratories. Increasing the range of tests available for use on the IDS-iSYS platform will continue to enhance the value of the system. The first ever automated test for 1,25-Dihydroxy Vitamin D is expected to be launched around the end of the current financial year and IDS-iSYS tests for hypertension (Renin and Aldosterone) are expected to be launched in the first quarter of the next financial year. This will make the IDS-iSYS the first automated system with both these tests. During the next financial year the Company expects to launch an additional three new tests in the areas of bone, hypertension and diabetes, further expanding the menu and differentiating the platform. The Company will also continue to pursue additional out-licensing opportunities for the IDS-iSYS technology. Outlook The Board expects overall revenues to show similar year on year growth in the new financial year with the decline in manual test sales being offset by increased IDS-iSYS revenues arising from new placements and additional products becoming available on the IDS-iSYS system. As a result of the combined impact of the factors and actions outlined above, the Board expects profit growth to resume in the new financial year. | ![]() stegrego | |
23/1/2012 08:24 | IDH been absolutely hammered this morning. Expected to see a knock-on effect on ODX from that, but not yet, it's actually up a bit. | ![]() codek | |
21/1/2012 13:01 | Something has happened to increase volumn? | ![]() leedslad001 | |
20/1/2012 18:56 | Im still following here. Every beaten up small cap has a chart like this one this week, in fact most have had stronger rises, so i wouldn't read too much into it. | ![]() davydoo | |
20/1/2012 16:51 | You can tell this is off the radar as only 4 of us here. lol longshanks as you say,I would like a few more myself on the cheap :-) | ![]() leedslad001 | |
20/1/2012 15:47 | Nice to see that second tick up. | ![]() monis | |
20/1/2012 15:40 | Damn all these other interlopers. I've been steadily acquiring stock and I still don't have as many as I would like. Still nice to have a bit of support for a change: has there been a tip somewhere? | ![]() longshanks | |
13/1/2012 15:38 | £500 top up today | ![]() leedslad001 | |
12/1/2012 12:59 | I wouldn't exactly say IDH is struggling. Struggling to maintain the stellar rate of growth seen over the last couple of years maybe but that slowdown is more to do with growing competition than tightening markets. Market for ODX is still fairly nascent and plenty of growth potential exists. If they get to be valued > £100m in a few years time then I for one will be very happy. | ![]() longshanks | |
12/1/2012 09:08 | IDH struggling.....speci | ![]() trustman | |
10/1/2012 14:49 | Wish i had some spare cash i would be buying. Spoke to the company about the share price decline, Small retail sellers at the moment so mm's can mark it down to suit themselves as no buying pressure. | ![]() leedslad001 | |
10/1/2012 09:53 | In the last results. As noted in the recent trading update the visibility of Allergozyme(R) export sales remains uncertain and customer evaluations in certain overseas markets are taking longer than first anticipated, but the Directors remain confident in this range of products. Could be a profit warning coming, need to see a trading update. | ![]() tech | |
10/1/2012 09:48 | This is getting pretty miserable. Market cap will soon be below the capital raised last year! Good time for those buying in but how low will it go? | ![]() longshanks | |
04/1/2012 12:57 | Will we get an RNS ? Wonder who bought them? | ![]() leedslad001 | |
04/1/2012 11:27 | chunky trade reported: worked sale? That might explain why the price tanked before Xmas. Could be due a nice rebound soon....one of my 5 for the UK Stock Challenge. | ![]() longshanks | |
22/12/2011 09:21 | Happy Christmas to you! | ![]() philo124 | |
22/12/2011 09:09 | Happy Christmas everyone | ![]() leedslad001 | |
06/12/2011 11:16 | We know there is a 100000 roll out there as well so the MM's have full control at the moment. Not gonna let them out at a good price. So anyone with any spare cash is been given a great chance to buy more at the moment. | ![]() leedslad001 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions